• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

勘误：一项关于度伐利尤单抗用于不可切除的 III 期非小细胞肺癌同步或序贯放化疗后的真实世界、多中心、观察性回顾性研究。

Corrigendum: A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer.

作者信息

Bruni Alessio, Scotti Vieri, Borghetti Paolo, Vagge Stefano, Cozzi Salvatore, D'Angelo Elisa, Giaj Levra Niccolò, Fozza Alessandra, Taraborrelli Maria, Piperno Gaia, Vanoni Valentina, Sepulcri Matteo, Trovò Marco, Nardone Valerio, Lattanzi Elisabetta, Bou Selman Said, Bertolini Federica, Franceschini Davide, Agustoni Francesco, Jereczek-Fossa Barbara Alicja, Magrini Stefano Maria, Livi Lorenzo, Lohr Frank, Filippi Andrea Riccardo

机构信息

Radiotherapy Unit, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.

Department of Oncology, Radiation Therapy Unit, Careggi University Hospital, Florence, Italy.

出版信息

Front Oncol. 2021 Nov 16;11:802949. doi: 10.3389/fonc.2021.802949. eCollection 2021.

DOI:10.3389/fonc.2021.802949
PMID:34869046
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8637883/
Abstract

[This corrects the article DOI: 10.3389/fonc.2021.744956.].

摘要

[本文更正了文章的数字对象标识符：10.3389/fonc.2021.744956。]

相似文献

1
Corrigendum: A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer.勘误：一项关于度伐利尤单抗用于不可切除的 III 期非小细胞肺癌同步或序贯放化疗后的真实世界、多中心、观察性回顾性研究。
Front Oncol. 2021 Nov 16;11:802949. doi: 10.3389/fonc.2021.802949. eCollection 2021.
2
A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer.一项关于度伐利尤单抗用于不可切除的 III 期非小细胞肺癌同步或序贯放化疗后的真实世界、多中心、观察性回顾性研究。
Front Oncol. 2021 Sep 28;11:744956. doi: 10.3389/fonc.2021.744956. eCollection 2021.
3
Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study.度伐鲁单抗作为不可切除的III期非小细胞肺癌患者同步放化疗（CCRT）后的巩固治疗：一项多中心观察性研究
Vaccines (Basel). 2021 Oct 1;9(10):1122. doi: 10.3390/vaccines9101122.
4
Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.免疫检查点抑制剂联合放化疗治疗不可切除 III 期非小细胞肺癌。
Lung Cancer. 2019 Aug;134:259-267. doi: 10.1016/j.lungcan.2019.05.027. Epub 2019 May 29.
5
Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study.在 III 期非小细胞肺癌患者中，与单纯放化疗相比，放化疗后使用度伐利尤单抗治疗与接受单纯放化疗的历史队列比较：一项真实世界多中心研究。
Eur J Cancer. 2021 Jan;142:83-91. doi: 10.1016/j.ejca.2020.10.008. Epub 2020 Nov 24.
6
DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy.度伐利尤单抗联合放疗用于不可切除的 III 期 NSCLC 患者，这些患者由于不适合化疗而无法接受化疗。
Future Oncol. 2021 Dec;17(34):4657-4663. doi: 10.2217/fon-2021-0952. Epub 2021 Nov 15.
7
Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.根据 PACIFIC 研究标准，在临床实践中符合接受度伐利尤单抗巩固治疗条件的不可切除 III 期非小细胞肺癌患者。
Respir Investig. 2019 Sep;57(5):466-471. doi: 10.1016/j.resinv.2019.03.011. Epub 2019 May 16.
8
Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy - single institute experience.序贯或同步放化疗后 durvalumab 治疗 III 期非小细胞肺癌患者的临床结局 - 单中心经验。
Radiol Oncol. 2021 Nov 19;55(4):482-490. doi: 10.2478/raon-2021-0044.
9
Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.局部晚期不可切除肺癌管理中的未满足临床需求：改善患者结局的治疗策略。
Adv Ther. 2019 Mar;36(3):563-578. doi: 10.1007/s12325-019-0876-4. Epub 2019 Jan 29.
10
Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer.在不可切除的 III 期非小细胞肺癌的真实世界患者中，放化疗后使用度伐利尤单抗进行巩固治疗。
Thorac Cancer. 2020 Jun;11(6):1541-1549. doi: 10.1111/1759-7714.13426. Epub 2020 Apr 13.

引用本文的文献

1
Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR).度伐鲁单抗可延长总生存期，而放射剂量增加至>66 Gy可能会改善不可切除的III期非小细胞肺癌的长期局部控制：奥地利放射肿瘤学肺癌研究协会注册研究（ALLSTAR）的更新分析。
Cancers (Basel). 2025 Apr 25;17(9):1443. doi: 10.3390/cancers17091443.
2
Immunotherapy Improves Clinical Outcome in Kirsten Rat Sarcoma Virus-Mutated Patients with Unresectable Non-Small Cell Lung Cancer Stage III: A Subcohort Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR).免疫疗法改善 Kirsten 大鼠肉瘤病毒突变的不可切除 III 期非小细胞肺癌患者的临床结局：奥地利放射肿瘤学肺癌研究协会登记处（ALLSTAR）的亚队列分析
J Clin Med. 2025 Feb 1;14(3):945. doi: 10.3390/jcm14030945.
3
Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review.免疫肿瘤治疗对胶质母细胞瘤患者的临床疗效：一项系统综述。
Brain Sci. 2023 Jan 17;13(2):159. doi: 10.3390/brainsci13020159.
4
Stereotactic Body Radiation Therapy (SBRT) for Oligorecurrent/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: A Systematic Review.立体定向体部放射治疗（SBRT）用于寡复发/寡进展性纵隔和肺门淋巴结转移：一项系统评价
Cancers (Basel). 2022 May 28;14(11):2680. doi: 10.3390/cancers14112680.